These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 22573342)

  • 1. Induction of pancreatic cancer cell apoptosis and enhancement of gemcitabine sensitivity by RAP80 siRNA.
    Li Y; Gu WJ; Liu HL
    Dig Dis Sci; 2012 Aug; 57(8):2072-8. PubMed ID: 22573342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of pancreatic cancer cell apoptosis, invasion, migration, and enhancement of chemotherapy sensitivity of gemcitabine, 5-FU, and oxaliplatin by hnRNP A2/B1 siRNA.
    Gu WJ; Liu HL
    Anticancer Drugs; 2013 Jul; 24(6):566-76. PubMed ID: 23525071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. siRNA directed against survivin enhances pancreatic cancer cell gemcitabine chemosensitivity.
    Liu WS; Yan HJ; Qin RY; Tian R; Wang M; Jiang JX; Shen M; Shi CJ
    Dig Dis Sci; 2009 Jan; 54(1):89-96. PubMed ID: 18594980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting X-linked inhibitor of apoptosis protein inhibits pancreatic cancer cell growth through p-Akt depletion.
    Jiang C; Yi XP; Shen H; Li YX
    World J Gastroenterol; 2012 Jun; 18(23):2956-65. PubMed ID: 22736919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small interfering RNA against the apurinic or apyrimidinic endonuclease enhances the sensitivity of human pancreatic cancer cells to gemcitabine in vitro.
    Xiong GS; Sun HL; Wu SM; Mo JZ
    J Dig Dis; 2010 Aug; 11(4):224-30. PubMed ID: 20649735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silencing of X-linked inhibitor of apoptosis (XIAP) decreases gemcitabine resistance of pancreatic cancer cells.
    Shrikhande SV; Kleeff J; Kayed H; Keleg S; Reiser C; Giese T; Büchler MW; Esposito I; Friess H
    Anticancer Res; 2006; 26(5A):3265-73. PubMed ID: 17094439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis.
    Schniewind B; Christgen M; Kurdow R; Haye S; Kremer B; Kalthoff H; Ungefroren H
    Int J Cancer; 2004 Mar; 109(2):182-8. PubMed ID: 14750167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. hTERT-siRNA could potentiate the cytotoxic effect of gemcitabine to pancreatic cancer cells Bxpc-3.
    Tan J; Zhou X; Zhu H
    Exp Clin Transplant; 2012 Aug; 10(4):386-93. PubMed ID: 22757972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emodin reverses gemcitabine resistance in pancreatic cancer cells via the mitochondrial apoptosis pathway in vitro.
    Liu DL; Bu H; Li H; Chen H; Guo HC; Wang ZH; Tong HF; Ni ZL; Liu HB; Lin SZ
    Int J Oncol; 2012 Apr; 40(4):1049-57. PubMed ID: 22159556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. siRNA directed against TrkA sensitizes human pancreatic cancer cells to apoptosis induced by gemcitabine through an inactivation of PI3K/Akt-dependent pathway.
    Liu D; Zhang Y; Dang C; Ma Q; Lee W; Chen W
    Oncol Rep; 2007 Sep; 18(3):673-7. PubMed ID: 17671718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [An experimental study of gemcitabine inducing pancreatic cancer cell apoptosis potentiated by nuclear factor-kappa B P65 siRNA].
    Kong R; Sun B; Wang SJ; Pan SH; Wang G; Chen H; Xue DB; Jiang HC
    Zhonghua Wai Ke Za Zhi; 2010 Jan; 48(2):128-33. PubMed ID: 20302733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies.
    Réjiba S; Bigand C; Parmentier C; Hajri A
    Neoplasia; 2009 Jul; 11(7):637-50. PubMed ID: 19568409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. pERK1/2 silencing sensitizes pancreatic cancer BXPC-3 cell to gemcitabine-induced apoptosis via regulating Bax and Bcl-2 expression.
    Wang M; Lu X; Dong X; Hao F; Liu Z; Ni G; Chen D
    World J Surg Oncol; 2015 Feb; 13():66. PubMed ID: 25880226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression.
    Tang K; Zhang Z; Bai Z; Ma X; Guo W; Wang Y
    Oncol Rep; 2011 Apr; 25(4):963-70. PubMed ID: 21225236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Down-regulation of Notch1 by small interfering RNA enhances chemosensitivity to gemcitabine in pancreatic cancer cells through activating apoptosis activity].
    Du X; Wang YH; Wang ZQ; Cheng Z; Li Y; Hu JK; Chen ZX; Zhou ZG
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2014 May; 43(3):313-8. PubMed ID: 24998655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
    Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
    Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Andrographolide causes apoptosis via inactivation of STAT3 and Akt and potentiates antitumor activity of gemcitabine in pancreatic cancer.
    Bao GQ; Shen BY; Pan CP; Zhang YJ; Shi MM; Peng CH
    Toxicol Lett; 2013 Sep; 222(1):23-35. PubMed ID: 23845849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergy of gemcitabine and lidamycin associated with NF-kappaB downregulation in pancreatic carcinoma cells.
    Chen J; Wu SY; Ou-Yang ZG; Zhen YS
    Acta Pharmacol Sin; 2008 May; 29(5):614-9. PubMed ID: 18430374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Experimental study of the function and mechanism combining dihydroartemisinin and gemcitabine in treating pancreatic cancer].
    Wang SJ; Sun B; Pan SH; Chen H; Kong R; Li J; Xue DB; Bai XW; Jiang HC
    Zhonghua Wai Ke Za Zhi; 2010 Apr; 48(7):530-4. PubMed ID: 20646665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced effect of gemcitabine by emodin against pancreatic cancer in vivo via cytochrome C-regulated apoptosis.
    Chen H; Wei W; Guo Y; Liu A; Tong H; Wang Z; Tan W; Liu J; Lin S
    Oncol Rep; 2011 May; 25(5):1253-61. PubMed ID: 21305255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.